Synergy CHC (SNYR)
NASDAQ:SNYR
Want to see SNYR full AI Analyst Report?
Top Page
Synergy CHC
(NASDAQ:SNYR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.38
▼(-76.93% Downside)
Action:UpgradedDate:04/30/26
The score is held down primarily by weak financial performance (losses, declining revenue, negative equity, and mostly negative cash flow) and very bearish technicals (well below key moving averages with depressed momentum). Earnings-call commentary provides some offset via margin/strategy and liquidity improvements, but recent financing/covenant changes and the license termination reinforce elevated risk.
Positive Factors
Beverage business traction and new retail distribution
Early beverage revenue and concrete retail wins demonstrate product-market fit and a new growth vector beyond legacy supplements. Large on-hand RTD inventory and expanded retailers create a scalable channel that can materially diversify revenue and reduce concentration risk over the next 2–6 months.
Negative Factors
Stressed balance sheet with negative equity
Negative equity and material debt mean a thin capital cushion and limited financial flexibility. This structural weakness raises refinancing risk, constrains strategic investments, and makes the firm vulnerable to operating setbacks or adverse covenant tests over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Beverage business traction and new retail distribution
Early beverage revenue and concrete retail wins demonstrate product-market fit and a new growth vector beyond legacy supplements. Large on-hand RTD inventory and expanded retailers create a scalable channel that can materially diversify revenue and reduce concentration risk over the next 2–6 months.
Read all positive factors
Synergy CHC (SNYR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.77M
Dividend YieldN/A
Average Volume (3M)136.07K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth-12.78%
EPS Growth-156.47%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-1.27
Shares Outstanding14,781,883
10 Day Avg. Volume89,526
30 Day Avg. Volume136,069
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.78
Price to Sales (P/S)0.60
P/FCF Ratio-7.00
Enterprise Value/Market Cap4.85
Enterprise Value/Revenue0.92
Enterprise Value/Gross Profit1.38
Enterprise Value/Ebitda-4.55
Forecast
1Y Price Target
$5.50Price Target Upside237.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.31
Revenue Forecast (FY)$44.71M
Synergy CHC Business Overview & Revenue Model
Company Description
Synergy CHC Corp. provides consumer health care, beauty, and lifestyle products in the United States, Canada, and the United Kingdom. It offers brain health nutritional supplements under the FOCUSfactor brand name; lifestyle products and accessori...
Synergy CHC Earnings Call Summary
Earnings Call Date:Apr 01, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 06, 2026
Earnings Call Sentiment Neutral
The call presents a mixed picture. Material one-time charges (notably a $6.66M bad debt allowance, inventory and media write-offs, and a ~$2.9M license revenue reversal) produced large GAAP losses and pushed operating expenses and adjusted EBITDA down. Offsetting these negatives, management highlighted meaningful strategic progress: beverage early traction (Q1 2026 > all of 2025), Mexico subsidiary and Costco Mexico entry, expanded Kroger distribution, stronger cash and working capital, and management’s contention that normalized gross margins are healthy. Operational risks remain (Flat Tummy weakness, TV advertising not restarted, and elevated inventory levels), but management frames many of the financial setbacks as one-time items with a path to improved normalized performance. Overall, positives and negatives are balanced.Positive Updates
Beverage Business Early Momentum
Generated over $600,000 in gross revenue in Q1 2026 (surpassing all of 2025 beverage revenue), implying a ~$2.5M 2026 run rate; millions of RTD and shot cans in stock and new distribution wins including EG of America (Cumberland Farms), Wakefern Foods, and multiple regional distributors.
Negative Updates
Q4 Revenue Decline and License Reversal
Q4 net revenue was $6.07M vs $10.27M year-ago, a 41% decrease; management reversed ~$2.9M of licensing revenue tied to a terminated UAE/Turkey agreement (CFO cited $2.9M reversal), which materially reduced reported revenue. Excluding the reversal, Q4 revenue would have been $8.97M (a 12.7% YOY decrease).
Read all updates
Q4-2025 Updates
Positive
Negative
Beverage Business Early Momentum
Generated over $600,000 in gross revenue in Q1 2026 (surpassing all of 2025 beverage revenue), implying a ~$2.5M 2026 run rate; millions of RTD and shot cans in stock and new distribution wins including EG of America (Cumberland Farms), Wakefern Foods, and multiple regional distributors.
Read all positive updates
Company Guidance
Management guided that normalized gross margin should maintain or improve (Q4 adjusted ~68.8%, FY adjusted ~70.3%), expects the Beverage division to accelerate in 2026 after generating >$600k in Q1 gross revenue (implying a ~$2.5M run-rate), with millions of RTD/shot cans in inventory and new distribution push (EG of America/Cumberland Farms, Wakefern, Costco roadshows, anticipated BJ’s), plans to reactivate TV advertising to drive at least a 15% same‑store sales lift for supplements (3 new SKUs shipped to all 1,600 Kroger stores), and said the balance sheet supports execution with $2.6M cash, $3.7M inventory, a $1.78M working‑capital surplus and improved operating cash use ($2.6M vs $4.8M prior year).Synergy CHC Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 30.38M | 34.83M | 42.78M | 38.41M | 40.23M |
| Gross Profit | 20.30M | 23.64M | 32.08M | 12.96M | 25.55M |
| EBITDA | -6.17M | 6.47M | 10.84M | -25.81M | 2.81M |
| Net Income | -12.34M | 2.12M | 6.34M | -32.63M | 1.41M |
Balance Sheet | |||||
| Total Assets | 10.16M | 16.34M | 12.24M | 18.54M | 12.59M |
| Cash, Cash Equivalents and Short-Term Investments | 2.62M | 687.92K | 632.53K | 1.93M | 1.67M |
| Total Debt | 26.81M | 27.52M | 27.62M | 22.83M | 8.75M |
| Total Liabilities | 33.29M | 32.97M | 39.55M | 52.06M | 16.27M |
| Stockholders Equity | -23.13M | -16.63M | -27.31M | -33.52M | -3.68M |
Cash Flow | |||||
| Free Cash Flow | -2.59M | -4.80M | 421.73K | -8.43M | -1.59M |
| Operating Cash Flow | -2.59M | -4.80M | 421.73K | -8.43M | -1.59M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 4.65M | 4.80M | -2.09M | 8.96M | 1.95M |
Synergy CHC Technical Analysis
Negative
1.63
Price Trends
1.22
Negative
1.55
Negative
2.15
Negative
Market Momentum
-0.22
Positive
19.58
Positive
16.66
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNYR, the sentiment is Negative. The current price of 1.63 is above the 20-day moving average (MA) of 0.87, above the 50-day MA of 1.22, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 19.58 is Positive, neither overbought nor oversold. The STOCH value of 16.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNYR.
Synergy CHC Peers Comparison
UnderperformOutperform
Sector (51)
SNYR
Synergy CHC
0.39
-1.44
-78.69%
RDGT
Ridgetech
1.56
-155.94
-99.01%
GEG
Great Elm Group
2.14
0.22
11.57%
WGRX
Wellgistics Health Inc
0.08
-2.48
-96.72%
Synergy CHC Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Synergy CHC Amends Term Loan, Issues Contingent Warrant
Negative
Mar 25, 2026
On March 24, 2026, Synergy CHC amended its term loan credit agreement with ACP Agency and lenders, revising the amortization schedule, interest mechanics, pricing, leverage and EBITDA covenants, and rules for using equity issuance proceeds. The co...
Business Operations and StrategyFinancial Disclosures
Synergy CHC Brand License Terminated, Eyes Direct Expansion
Negative
Mar 4, 2026
On February 27, 2026, Synergy CHC Corp. was informed by Gravity Pharma General Trading LLC that Gravity was terminating from inception their Brand License Agreement, originally signed on March 31, 2025 and amended June 30, 2025, which had granted ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.